JP7590871B2 - 抗ｍｓｒ１抗体及びその使用方法 - Google Patents

抗ｍｓｒ１抗体及びその使用方法 Download PDF

Info

Publication number
JP7590871B2
JP7590871B2 JP2020562649A JP2020562649A JP7590871B2 JP 7590871 B2 JP7590871 B2 JP 7590871B2 JP 2020562649 A JP2020562649 A JP 2020562649A JP 2020562649 A JP2020562649 A JP 2020562649A JP 7590871 B2 JP7590871 B2 JP 7590871B2
Authority
JP
Japan
Prior art keywords
antibody
alkyl
formula
msr1
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020562649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523147A (ja
JPWO2019217591A5 (enExample
Inventor
キラトソウス クリストス
ニットーリ トーマス
ズムステグ アンナ
グロマダ ジャスパー
グサロバ ヴィクトリア
ハン エイミー
ハジナスト ソコル
ジェイ． マーフィー アンドリュー
オルソン ウィリアム
スリーマン マシュー
Original Assignee
レゲネロン ファーマシューティカルス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レゲネロン ファーマシューティカルス，インコーポレーテッド filed Critical レゲネロン ファーマシューティカルス，インコーポレーテッド
Publication of JP2021523147A publication Critical patent/JP2021523147A/ja
Publication of JPWO2019217591A5 publication Critical patent/JPWO2019217591A5/ja
Priority to JP2024091536A priority Critical patent/JP2024133471A/ja
Application granted granted Critical
Publication of JP7590871B2 publication Critical patent/JP7590871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
JP2020562649A 2018-05-09 2019-05-08 抗ｍｓｒ１抗体及びその使用方法 Active JP7590871B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091536A JP2024133471A (ja) 2018-05-09 2024-06-05 抗ｍｓｒ１抗体及びその使用方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862669276P 2018-05-09 2018-05-09
US62/669,276 2018-05-09
US201862678200P 2018-05-30 2018-05-30
US62/678,200 2018-05-30
US201862769946P 2018-11-20 2018-11-20
US62/769,946 2018-11-20
US201962789987P 2019-01-08 2019-01-08
US62/789,987 2019-01-08
US201962821362P 2019-03-20 2019-03-20
US62/821,362 2019-03-20
PCT/US2019/031383 WO2019217591A1 (en) 2018-05-09 2019-05-08 Anti-msr1 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091536A Division JP2024133471A (ja) 2018-05-09 2024-06-05 抗ｍｓｒ１抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021523147A JP2021523147A (ja) 2021-09-02
JPWO2019217591A5 JPWO2019217591A5 (enExample) 2022-06-02
JP7590871B2 true JP7590871B2 (ja) 2024-11-27

Family

ID=66625372

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562649A Active JP7590871B2 (ja) 2018-05-09 2019-05-08 抗ｍｓｒ１抗体及びその使用方法
JP2024091536A Pending JP2024133471A (ja) 2018-05-09 2024-06-05 抗ｍｓｒ１抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091536A Pending JP2024133471A (ja) 2018-05-09 2024-06-05 抗ｍｓｒ１抗体及びその使用方法

Country Status (15)

Country Link
US (2) US11377502B2 (enExample)
EP (1) EP3790899A1 (enExample)
JP (2) JP7590871B2 (enExample)
KR (1) KR20210008008A (enExample)
CN (2) CN112533951A (enExample)
AU (1) AU2019265703A1 (enExample)
BR (1) BR112020022400A2 (enExample)
CA (1) CA3098453A1 (enExample)
CL (1) CL2020002873A1 (enExample)
CO (1) CO2020015084A2 (enExample)
MX (1) MX2020011546A (enExample)
MY (1) MY209590A (enExample)
PH (1) PH12020551865A1 (enExample)
SG (1) SG11202010909RA (enExample)
WO (1) WO2019217591A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250114431A (ko) 2016-11-08 2025-07-29 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
CA3063872A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
CN110944718A (zh) 2017-05-18 2020-03-31 里珍纳龙药品有限公司 环糊精蛋白质药物偶联物
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
JP7366028B2 (ja) 2018-01-08 2023-10-20 レゲネロン ファーマシューティカルス，インコーポレーテッド ステロイド及びその抗体コンジュゲート
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
US12209180B2 (en) 2018-11-20 2025-01-28 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists
MA54545A (fr) * 2018-12-21 2021-10-27 Regeneron Pharma Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci
EP3908323A2 (en) 2019-01-08 2021-11-17 Regeneron Pharmaceuticals, Inc. Traceless linkers and protein-conjugates thereof
WO2021257539A1 (en) * 2020-06-16 2021-12-23 Academia Sinica ANTIBODIES TO INTERLEUKIN-1β AND USES THEREOF
IL299153A (en) * 2020-07-13 2023-02-01 Regeneron Pharma Camptothecin analogs conjugated to a glutamine residue in protein, and their uses
CN114605367B (zh) * 2020-12-03 2023-06-27 中国人民解放军军事科学院军事医学研究院 含香豆素的连接子及含该连接子的抗体偶联药物
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
JP2024511165A (ja) * 2021-03-26 2024-03-12 リジェネロン ファーマシューティカルズ，インク． バンコマイシンと組み合わせたリファマイシン類似体およびその使用
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CN115671309B (zh) * 2021-07-30 2025-05-09 北京键凯科技股份有限公司 一种抗体-siRNA药物偶联物
CN115671308B (zh) * 2021-07-30 2025-11-14 北京键凯科技股份有限公司 一种靶向性的抗体-聚乙二醇-siRNA药物偶联物
CN115594766A (zh) * 2021-12-30 2023-01-13 辽宁键凯科技有限公司（Cn） 一种缀合物及用其制备的抗体偶联药物
CN118829449A (zh) * 2022-01-12 2024-10-22 瑞泽恩制药公司 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
CN119325392A (zh) 2022-03-11 2025-01-17 萤火虫生物股份有限公司 苯基马来酰亚胺连接剂
EP4587030A2 (en) * 2022-09-15 2025-07-23 Adcentrx Therapeutics Inc. Novel glucocorticoid receptor agonists and immunoconjugates thereof
EP4661914A1 (en) 2023-02-09 2025-12-17 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates via inverse electron demand diels-alder reactions
TW202519268A (zh) * 2023-09-11 2025-05-16 美商卡蒂那生物科學股份有限公司 多肽結合組合物及使用方法
WO2025228390A1 (en) * 2024-04-30 2025-11-06 Hutchmed Limited A hydrophilic linker, antibody drug conjugate and use thereof
CN120399078A (zh) * 2025-05-08 2025-08-01 上海天泽云泰生物医药有限公司 靶向cd117的纳米抗体及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119266A1 (en) 2004-06-03 2005-12-15 Universiteit Leiden Sr-a antagonists
WO2010010119A1 (en) 2008-07-22 2010-01-28 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
WO2011103389A1 (en) 2010-02-19 2011-08-25 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
WO2012011591A1 (ja) 2010-07-23 2012-01-26 武田薬品工業株式会社 縮合複素環化合物およびその用途
WO2015153401A1 (en) 2014-04-04 2015-10-08 Merck Sharp & Dohme Corp Phosphate based linkers for intracellular delivery of drug conjugates
WO2017199046A1 (en) 2016-05-20 2017-11-23 Polytherics Limited Conjugates and conjugating reagents

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2920999A (en) 1957-06-07 1960-01-12 Pfizer & Co C 21-nitrogen derivatives of corticosteroids
DE1165595B (de) 1958-03-04 1964-03-19 Olin Mathieson Verfahren zur Herstellung von Triamcinolonacetonid-21-hemisuccinat und dessen Salzen
GB889766A (en) 1958-03-04 1962-02-21 Olin Mathieson Improvements in steroids and the synthesis thereof
US3197469A (en) 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3007923A (en) 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
GB898295A (en) 1959-03-18 1962-06-06 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
US3033873A (en) 1960-05-11 1962-05-08 Pfizer & Co C 21-aminomethyl-pregnenes
US3033874A (en) 1960-05-11 1962-05-08 Pfizer & Co C 17beta-propenoyl steroids and process for preparing same
US3020275A (en) 1960-06-07 1962-02-06 American Cyanamid Co 21-nitrogen substituted steroids of the pregnane series and methods of preparing the same
DE1169444B (de) 1961-02-22 1964-05-06 Schering Ag Verfahren zur Herstellung von ?-16ª‡-Methylsteroiden
US3047468A (en) 1961-06-06 1962-07-31 American Cyanamid Co Method of preparing delta1, 4-3-keto steroids of the pregnane series
US3383394A (en) 1965-08-30 1968-05-14 Schering Corp Novel 17-acylating process and products thereof
US3798216A (en) 1969-03-07 1974-03-19 Fabrication Des Antibiotique S 9-fluoro-11beta,21-dihydroxy-16alpha,17-(2-propenylidenedioxy)-pregna-1,4-diene-3,20-dione and derivatives thereof
DE2047105C3 (de) 1970-09-18 1979-02-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen 17-Chlorsteroide und Verfahren zu ihrer Herstellung
IT1057859B (it) 1972-04-28 1982-03-30 Sigma Tao Ind Farmaceutiche Sp Perivato del triamoinolone
SE378109B (enExample) 1972-05-19 1975-08-18 Bofors Ab
SE378110B (enExample) 1972-05-19 1975-08-18 Bofors Ab
US4076737A (en) 1975-02-20 1978-02-28 Ciba-Geigy Corporation Aldehydes of the pregnane series and derivatives thereof
IL73337A (en) 1984-10-28 1988-09-30 Yissum Res Dev Co Antitumor steroid-platinum complexes and method for the preparation thereof
SE8604059D0 (sv) 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5116829A (en) 1990-04-23 1992-05-26 Kao Corporation Steroid compounds
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
SK87295A3 (en) 1993-01-08 1996-04-03 Astra Ab Novel colon or ileum-specific steroid derivatives
DE4311987A1 (de) 1993-04-07 1994-10-13 Schering Ag Neue Glucocorticoide
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5837698A (en) 1996-05-02 1998-11-17 G. D. Searle & Co. Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
AU3703900A (en) 1999-02-24 2000-09-14 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
SE0101220D0 (sv) 2001-04-04 2001-04-04 Astrazeneca Ab New use
US6908934B2 (en) 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
ITMI20020148A1 (it) 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
US7190468B2 (en) 2002-07-17 2007-03-13 Hewlett-Packard Development Company, L.P. Background document rendering system and method
PT2357006E (pt) 2002-07-31 2016-01-22 Seattle Genetics Inc Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
AU2003265576A1 (en) 2002-08-23 2004-03-11 The Mclean Hospital Corporation Corticosteroid conjugates and uses thereof
KR20120104412A (ko) 2002-09-06 2012-09-20 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
CN1414008A (zh) 2002-10-17 2003-04-30 南开大学 含氮甾体化合物及其制备方法
US7015349B2 (en) 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005063777A1 (en) 2003-12-23 2005-07-14 Corus Pharma Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
US8101714B2 (en) * 2004-02-18 2012-01-24 The University Of Georgia Research Foundation, Inc. Teleost derived antimicrobial polypeptides
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
US20050192257A1 (en) 2004-02-26 2005-09-01 Peyman Gholam A. Predictors for patients at risk for glaucoma from steroid therapy
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
DE602004017164D1 (de) 2004-08-09 2008-11-27 Deutsches Krebsforsch Albuminkonjugate, die eine Glucuron-Verknüpfung enthalten
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
WO2006135371A1 (en) 2005-06-09 2006-12-21 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
US20100209508A1 (en) 2005-06-14 2010-08-19 Corus Pharma, Inc. Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008127347A1 (en) * 2006-07-21 2008-10-23 Diadexus, Inc. Pro115 antibody compositions and methods of use
CA2677441C (en) 2007-02-05 2016-04-12 Nicox S.A. Nitric oxide releasing steroids
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
DK2167963T3 (da) 2007-05-23 2019-06-24 Ventana Med Syst Inc Polymerbærere til immunhistokemi og in situ-hybridisering
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CA2692021A1 (en) 2007-06-28 2008-12-31 Capsutech Ltd Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
CN101397328A (zh) 2007-09-27 2009-04-01 天津药业研究院有限公司 一氧化氮供体型糖皮质激素
WO2009046446A2 (en) 2007-10-05 2009-04-09 Wayne State University Dendrimers for sustained release of compounds
PE20091525A1 (es) 2007-12-21 2009-09-25 Schering Corp Agonista del receptor glucocorticoide c-20-c21 sustituido
CN102099368A (zh) 2007-12-21 2011-06-15 先灵公司 作为糖皮质激素受体激动剂的c-21硫醚
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
JP2011522895A (ja) 2008-06-10 2011-08-04 ギリアード サイエンシーズ， インコーポレイテッド 治療において使用するためのβ−アゴニスト化合物と連結したコルチコステロイド
EP2326349B1 (en) 2008-07-21 2015-02-25 Polytherics Limited Novel reagents and method for conjugating biological molecules
CA2754589C (en) 2009-03-09 2013-07-16 Mikasa Seiyaku Co., Ltd. Steroid compound
WO2010126953A1 (en) 2009-04-29 2010-11-04 Gilead Sciences, Inc. Corticosteroid linked beta-agonist compounds for use in therapy
WO2010132743A1 (en) 2009-05-15 2010-11-18 Gilead Sciences, Inc. Corticosteroid beta-agonist compounds for use in therapy
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
TWI540136B (zh) 2010-04-15 2016-07-01 梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
CA3250882A1 (en) 2010-08-02 2025-11-29 Regeneron Pharamaceuticals, Inc. Mice that Make Binding Proteins Comprising VL Domains
DK2611785T3 (da) 2010-09-01 2014-08-25 Bayer Ip Gmbh N-(tetrazol-5yl)- og n- (triazol-5-yl) arylcarboxylsyreamider og deres anvendelse som herbicider
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
WO2012145632A1 (en) 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
MX345538B (es) 2011-05-27 2017-02-03 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9399073B2 (en) 2011-10-14 2016-07-26 Seattle Genetics, Inc. Pyrrolobenzodiazepines
WO2013055990A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EA026643B1 (ru) 2011-10-14 2017-04-28 Сиэтл Дженетикс, Инк. Пирролбензодиазепины и конъюгаты направленного действия
CA2850096C (en) 2011-10-14 2018-07-03 Spirogen Sarl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CA2857398A1 (en) 2011-12-05 2013-06-13 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
EA036225B1 (ru) 2012-03-14 2020-10-15 Ридженерон Фармасьютикалз, Инк. Мультиспецифические антигенсвязывающие молекулы и их применения
AU2013274078A1 (en) 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
HK1208813A1 (en) 2012-10-11 2016-03-18 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
EP2908818A4 (en) 2012-10-16 2016-07-13 Endocyte Inc CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
US9376420B2 (en) 2012-10-25 2016-06-28 Yuhan Corporation 4,5-dihydro-1H-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same
DK2935331T3 (en) 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
US9610361B2 (en) 2013-03-13 2017-04-04 Seattle Genetics, Inc. Cyclodextrin and antibody-drug conjugate formulations
US20160082119A1 (en) 2013-04-22 2016-03-24 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
AU2014283185B2 (en) 2013-06-21 2019-05-02 Araris Biotech Ltd. Enzymatic conjugation of polypeptides
US20160158369A1 (en) 2013-07-10 2016-06-09 Seikagaku Corporation Pharmaceutical composition for respiratory administration
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
KR102538993B1 (ko) 2013-10-15 2023-06-02 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
CN103694375B (zh) 2013-12-13 2016-10-05 北京大学 一种三萜-环糊精共价化合物及其制备方法和用途
JP6527171B2 (ja) 2014-01-24 2019-06-05 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック クローン病などの大腸菌誘発性炎症性腸疾患治療用の経口摂取可能な化合物、これを調製するプロセスおよび付着防止薬としての使用
PT3789042T (pt) 2014-04-10 2025-01-14 Daiichi Sankyo Europe Gmbh Método para produzir conjugado anticorpo-fármaco anti-her3
US9951141B2 (en) 2014-06-02 2018-04-24 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
EP3166638B1 (en) 2014-06-13 2025-08-06 Glykos Finland Oy Payload-polymer-protein conjugates
RU2017118792A (ru) 2014-12-03 2019-01-09 Дженентек, Инк. Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
BR112017011325A2 (pt) 2014-12-03 2020-07-21 Genentech, Inc. ?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
AU2015360621A1 (en) 2014-12-09 2017-06-29 Abbvie Inc. Bcl-xL inhibitory compounds and antibody drug conjugates including the same
EP3230282A1 (en) 2014-12-09 2017-10-18 AbbVie Inc. Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
WO2016120891A1 (en) 2015-01-30 2016-08-04 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
US20170224835A1 (en) 2015-02-06 2017-08-10 Sorrento Therapeutics, Inc. Antibody Drug Conjugates
JP6993958B2 (ja) * 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
WO2017006279A1 (en) 2015-07-08 2017-01-12 Aten Porus Lifesciences Cyclodextrin-polymer complexes and compostions and methods of making and using the same
CN117567535A (zh) 2015-09-10 2024-02-20 坦伯公司 生物正交组合物
EP3359194A4 (en) 2015-10-06 2019-04-24 Merck Sharp & Dohme Corp. ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
US10869929B2 (en) 2016-01-29 2020-12-22 Merck Sharp & Dohme Corp. Phosphonate linkers and their use to facilitate cellular retention of compounds
WO2017147542A2 (en) 2016-02-26 2017-08-31 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
RS62040B1 (sr) 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
CN109562168A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
KR20250114431A (ko) 2016-11-08 2025-07-29 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
TWI862991B (zh) 2017-02-28 2024-11-21 美商伊繆諾金公司 具有自分解肽連接子之類美登素衍生物及其結合物
CN110944718A (zh) 2017-05-18 2020-03-31 里珍纳龙药品有限公司 环糊精蛋白质药物偶联物
CA3063872A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
US11629122B2 (en) 2017-05-24 2023-04-18 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
WO2019034176A1 (zh) 2017-08-18 2019-02-21 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
WO2019034177A1 (zh) 2017-08-18 2019-02-21 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
CA3080857A1 (en) * 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
JP7366028B2 (ja) 2018-01-08 2023-10-20 レゲネロン ファーマシューティカルス，インコーポレーテッド ステロイド及びその抗体コンジュゲート
MA52669A (fr) 2018-04-06 2021-02-17 Seagen Inc Conjugués peptidiques de camptothécine
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
US12209180B2 (en) 2018-11-20 2025-01-28 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists
MA54545A (fr) 2018-12-21 2021-10-27 Regeneron Pharma Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci
EP3908323A2 (en) 2019-01-08 2021-11-17 Regeneron Pharmaceuticals, Inc. Traceless linkers and protein-conjugates thereof
US20230119539A1 (en) 2019-01-08 2023-04-20 Regeneron Pharmaceuticals, Inc. Traceless linkers and protein-conjugates thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119266A1 (en) 2004-06-03 2005-12-15 Universiteit Leiden Sr-a antagonists
WO2010010119A1 (en) 2008-07-22 2010-01-28 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
WO2011103389A1 (en) 2010-02-19 2011-08-25 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
WO2012011591A1 (ja) 2010-07-23 2012-01-26 武田薬品工業株式会社 縮合複素環化合物およびその用途
WO2015153401A1 (en) 2014-04-04 2015-10-08 Merck Sharp & Dohme Corp Phosphate based linkers for intracellular delivery of drug conjugates
WO2017199046A1 (en) 2016-05-20 2017-11-23 Polytherics Limited Conjugates and conjugating reagents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Ｂｉｏｃｏｎｊｕｇａｔｅ Ｃｈｅｍｉｓｔｒｙ，2016年07月28日，Ｖｏｌ．２７，Ｎｏ．９，ｐ２０８１－２０８８，doi: 10.1021/acs.bioconjchem.6b00337
CZERKIES M et al.，"An interplay between scavenger receptor A and CD14 during activation of J774 cells by high concentrations of LPS."，Immunobiology，2013年04月12日，Vol. 218, No. 10，p.1217-26
Drug Metab. Dispos.，1997年，25，1311-1317
Drug Metab. Dispos.，1998年，26，623-630
OZMENT, T. R. et al.，P222 BLOOD MONOCYTE SCAVENGER RECEPTOR A (CD204) EXPRESSION IS INCREASED IN SEPTIC PATIENTS，SHOCK，2016年，Vol.45, No.6S，p.129
P. I. MAKINEN et al.，"Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors"，Cardiovascular Research，2010年，Vol.88, No.3，p.530-538

Also Published As

Publication number Publication date
JP2024133471A (ja) 2024-10-02
BR112020022400A2 (pt) 2021-02-02
EP3790899A1 (en) 2021-03-17
KR20210008008A (ko) 2021-01-20
PH12020551865A1 (en) 2021-07-19
SG11202010909RA (en) 2020-12-30
US20190367631A1 (en) 2019-12-05
US12497460B2 (en) 2025-12-16
CN112533951A (zh) 2021-03-19
JP2021523147A (ja) 2021-09-02
AU2019265703A1 (en) 2020-11-19
CN118955710A (zh) 2024-11-15
WO2019217591A1 (en) 2019-11-14
CA3098453A1 (en) 2019-11-14
MX2020011546A (es) 2021-01-29
CL2020002873A1 (es) 2021-03-26
US11377502B2 (en) 2022-07-05
CO2020015084A2 (es) 2021-02-26
MY209590A (en) 2025-07-23
US20230079407A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
JP7590871B2 (ja) 抗ｍｓｒ１抗体及びその使用方法
JP7728636B2 (ja) ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート
JP7751054B2 (ja) リファマイシンアナログおよびその抗体薬物コンジュゲート
JP2024009905A (ja) ステロイド及びその抗体コンジュゲート
JP7702866B2 (ja) Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート
CN106573956A (zh) 澳瑞他汀衍生物及其缀合物
EA049203B1 (ru) Аналоги рифамицина и конъюгаты антитело-лекарственное средство с ними

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240605

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241115

R150 Certificate of patent or registration of utility model

Ref document number: 7590871

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150